One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The Platinum Hall of Fame
doi : 10.1016/j.eururo.2022.12.013
Volume 83, Issue 2, February 2023, Pages e35-e44
Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy
Laura S. Mertens a,*, Richard P. Meijer b , J. Alfred Witjes
doi : 10.1016/j.eururo.2022.09.017
Volume 83, Issue 2, February 2023, Pages 95-96
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist’s Point of View
Milan Hora a,*, Laurence Albiges b , Jens Bedke c,d , Riccardo Campi e,f,g , Umberto Capitanio h,i , Rachel H. Giles j , Bo ̈rje Ljungberg k , Lorenzo Marconi l , Tobias Klatte m , Alessandro Volpe n , Yasmin Abu-Ghanem o , Saeed Dabestani p , Sergio Ferna �ndez-Pello q , Fabian Hofmann r , Teele Kuusk s , Rana Tahbaz m , Thomas Powles t , Axel Bex u,v,w , Kiril Trpkov
doi : 10.1016/j.eururo.2022.11.001
Volume 83, Issue 2, February 2023, Pages 97-100
Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint
Kerrington Powell a , Michael C. Burns b , Vinay Prasad
doi : 10.1016/j.eururo.2022.08.029
Volume 83, Issue 2, February 2023, Pages 101-102
Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial
Sigrid V. Carlsson a,b,c , Rebecka Arnsrud Godtman c,d , Carl-Gustav Pihl e , Andrew Vickers b , Hans Lilja a,f,g,h , Jonas Hugosson c,d , Marianne Ma ÌŠ nsson c
doi : 10.1016/j.eururo.2022.10.006
Volume 83, Issue 2, February 2023, Pages 103-109
Screening for Prostate Cancer with Prostate-specific Antigen: The Journey Continues
Peter C. Albertsen
doi : 10.1016/j.eururo.2022.10.018
Volume 83, Issue 2, February 2023, Pages 110-111
Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer
Ethan S. Barnett a , Nikolaus Schultz b , Konrad H. Stopsack a , Ernest T. Lam c , Andrea Arfe b , Jerry Lee c , Jimmy L. Zhao a , Joseph D. Schonhoft c , Emily A. Carbone a , Niamh M. Keegan a , Andreas Wibmer d , Yipeng Wang c , David B. Solit a , Wassim Abida a , Richard Wenstrup c , Howard I. Scher
doi : 10.1016/j.eururo.2022.08.010
Volume 83, Issue 2, February 2023, Pages 112-120
BRCA2 alterations predict for a response to poly-ADP-ribose polymerase inhibition in metastatic castration-resistant prostate cancer (mCRPC). However, detection is hindered by insufficient tumor tissue and low sensitivity of cell-free DNA for detecting copy number loss.
Putting Precision Medicine in Prostate Cancer into Practice: Are We There Yet?
Christopher Logothetis *, Patrick Pilie
doi : 10.1016/j.eururo.2022.09.028
Volume 83, Issue 2, February 2023, Pages 121-124
Outpatient Photodynamic Diagnosis–guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis–guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial
Gyrithe Lynghøj Pedersen a,*, Marie Schmidt Erikson a , Karin Mogensen a , Susanne Rosthøj b , Gregers Gautier Hermann
doi : 10.1016/j.eururo.2022.08.012
Volume 83, Issue 2, February 2023, Pages 125-130
Transurethral resection of recurrent low-grade intermediate-risk Ta bladder tumor (BT) in general anesthesia (GA) is burdensome to patients and health care system. Laser technologies enable treatment in office-based settings, reducing morbidity and costs.
Is Office-based Management of Intermediate-risk Low-grade Non–muscle-invasive Bladder Cancer Ready For Prime Time?
Jacob Taylor, Yair Lotan
doi : 10.1016/j.eururo.2022.09.001
Volume 83, Issue 2, February 2023, Pages 131-132
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition
Franziska Erlmeier a,b,c,d,e , Niklas Klu ̈mper f,g,h , Laura Landgraf a,b,e , Pamela L. Strissel a,b,c,e,i , Reiner Strick b,c,e,i , Danijel Sikic b,c,e,j , Helge Taubert b,c,e,j , Sven Wach b,c,e,j , Carol I. Geppert a,b,e , Veronika Bahlinger a,b,c,e , Johannes Breyer c,e,k , Manuel Ritter c,f,h , Christian Bolenz c,l , Florian Roghmann c,m , Philipp Erben c,n , Kristina Schwamborn d,e , Ralph M. Wirtz c,o , Thomas Horn e,p , Bernd Wullich b,c,e,j , Michael Ho ̈lzel g,h , Arndt Hartmann a,b,c,e , Ju ̈rgen E. Gschwend e,p , Wilko Weichert d,e , Markus Eckstein
doi : 10.1016/j.eururo.2022.10.020
Volume 83, Issue 2, February 2023, Pages 133-142
TIME for a Change? Multimarker Assessment of the Tumour Immune Microenvironment and Metastatic Site Biopsy to Improve Immunotherapy Response Prediction in Muscle-invasive Bladder Cancer
Jon Griffin
doi : 10.1016/j.eururo.2022.11.008
Volume 83, Issue 2, February 2023, Pages 143-144
Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium
Ziad Bakouny a,b,c,y, Talal El Zarif b,c,y, Shaan Dudani d , J. Connor Wells e , Chun Loo Gan f , Frede Donskov g,h , Julia Shapiro i , Ian D. Davis j,k , Francis Parnis l , Praful Ravi b,c , John A. Steinharter b , Neeraj Agarwal m , Ajjai Alva n , Lori Wood o , Anil Kapoor p , Jose M. Ruiz Morales q , Christian Kollmannsberger r , Benoit Beuselinck s , Wanling Xie t,y, Daniel Y.C. Heng e,y, Toni K. Choueiri
doi : 10.1016/j.eururo.2022.10.004
Volume 83, Issue 2, February 2023, Pages 145-151
Primary Cytoreductive Nephrectomy: Standing the Test of Time?
Ithaar H. Derweesh a , Rana R. McKay b , Aditya Bagrodia
doi : 10.1016/j.eururo.2022.10.022
Volume 83, Issue 2, February 2023, Pages 152-153
Effect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial
Vladimir Student Jr. a,*, Zbynek Tudos b , Zuzana Studentova a , Ondrej Cesak a , Hana Studentova c , Vaclav Repa d , Dana Purova d , Vladimir Student
doi : 10.1016/j.eururo.2022.07.027
Volume 83, Issue 2, February 2023, Pages 154-162
Symptomatic lymphoceles present the most common complication of robot-assisted radical prostatectomy (RARP) with extended pelvic lymph node dissection (ePLND). No surgical technique has so far shown success in reducing the incidence rate, but several retrospective studies have shown the beneficial effect of the fixation of the peritoneum.
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
Yunze Xu a,y, Wen Kong a,y, Ming Cao a,y, Jieying Wang b , Zaoyu Wang c , Liang Zheng d , Xiaoyu Wu d , Rongrong Cheng d , Wei He c , Bo Yang e , Baijun Dong a , Jiahua Pan a , Yonghui Chen a , Jiwei Huang a , Chen Jiang a , Wei Zhai a , Fangzhou Li a , Ruohua Chen f , Xiang Zhou f , Guangyu Wu g , Xiaochuan Geng g , Jiasheng Chen h , Huimin An i , Yichu Yuan j , Tianyuan Xu k , Dongning Chen l , Dengqiang Lin m , Lieyu Xu n , Kangbo Huang o , Ling Peng p , Yanfei Yu q , Shengcheng Tai r , Honggang Qi s , Kai Luo t , Xiaonan Kang t , Hang Wang u , Yiran Huang a,*, Jin Zhang a,*, Wei Xue
doi : 10.1016/j.eururo.2022.05.029
Volume 83, Issue 2, February 2023, Pages 163-172
FH-deficient renal cell carcinoma (RCC) is a rare and exceptionally aggressive RCC subtype. There is currently limited understanding of the molecular alterations, pathogenesis, survival outcomes, and systemic therapy efficacy for this cancer.
Kidney Transplantation Outcome Predictions (KTOP): A Risk Prediction Tool for Kidney Transplants from Brain-dead Deceased Donors Based on a Large European Cohort
Gregor Miller a,*, Donna P. Ankerst a,b , Michael W. Kattan c , Norbert Hu ̈ser d,e , Serge Vogelaar f , Ineke Tieken f , Uwe Heemann d,g , Volker Assfalg
doi : 10.1016/j.eururo.2021.12.008
Volume 83, Issue 2, February 2023, Pages 173-179
European kidney donation shortages mandate efficient organ allocation by optimizing the prediction of success for individual recipients.
Genitourinary Symptoms Caused by Monkeypox Virus: What Urologists Should Know
Zhikang Yu a,y, Bo Zhu a,y, Qiuqiu Qiu b , Ning Ding a , Haiyang Wu c,d,*, Zefeng Shen
doi : 10.1016/j.eururo.2022.11.005
Volume 83, Issue 2, February 2023, Pages 180-182
Uncertainty Persists Regarding the Role of Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma with Favourable Prognosis
Chiara Ciccarese
doi : 10.1016/j.eururo.2022.10.026
Volume 83, Issue 2, February 2023, Pages e45-e46
Re: Spatially Resolved Clonal Copy Number Alterations in Benign and Malignant Tissue
Karol Axcrona a,b,* Kirsti Aas c Ulrika Axcrona b,d Rolf I. Skotheim
doi : 10.1016/j.eururo.2022.11.013
Volume 83, Issue 2, February 2023, Page 183
Re: Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction
Howard B. Goldman
doi : 10.1016/j.eururo.2022.11.015
Volume 83, Issue 2, February 2023, Page 184
Re: Thulium Fibre Laser versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial
Mariela Corrales Olivier Traxer
doi : 10.1016/j.eururo.2022.11.012
Volume 83, Issue 2, February 2023, Pages 184-185
Re: Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography
Marco Borghesi a,* Matteo Bauckneht b Carlo Terrone
doi : 10.1016/j.eururo.2022.11.016
Volume 83, Issue 2, February 2023, Pages 185-186
Re: Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death
Ana Plata Bello a,* Karim Touijer
doi : 10.1016/j.eururo.2022.12.006
Volume 83, Issue 2, February 2023, Pages 186-187
Re: Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer
Arnauld Villers * Jonathan Olivier
doi : 10.1016/j.eururo.2022.09.023
Volume 83, Issue 2, February 2023, Pages 187-188
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Suman Sahoo * Abhishek Pandey Swarnendu Mandal Manoj Kumar Das Prasant Nayak
doi : 10.1016/j.eururo.2022.10.027
Volume 83, Issue 2, February 2023, Page e47
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Wei Shen Tan a,b,* Connor Mustard c John D. Kelly a,d , on behalf of the HIVEC-II trial team
doi : 10.1016/j.eururo.2022.11.006
Volume 83, Issue 2, February 2023, Pages e48-e49
Re: Albert Martini, Nicolas Mottet, Francesco Montorsi, et al. A Plea for Economically Sustainable Evidence-based Guidelines. Eur Urol. 2022;82:449–51
Minxiong Hu Liefu Ye
doi : 10.1016/j.eururo.2022.10.023
Volume 83, Issue 2, February 2023, Pages e50-e51
Re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique. Eur Urol. 2022;82:551–58
Minxiong Hu Liefu Ye
doi : 10.1016/j.eururo.2022.09.036
Volume 83, Issue 2, February 2023, Pages e52-e53
Re: Khyati Meghani, Lauren Folgosa Cooley, Bonnie Choy, et al. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin. Eur Urol. 2022;82:602–10
Ryan L. Steinberg * Michael A. O’Donnell Vignesh T. Packiam
doi : 10.1016/j.eururo.2022.10.025
Volume 83, Issue 2, February 2023, Pages e54-e55
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Fabio Campodonico a,* Francesca Mattioli b,c Carlo Introini
doi : 10.1016/j.eururo.2022.09.035
Volume 83, Issue 2, February 2023, Pages e56-e57
Re: Juan Gómez Rivas, Bhaskar Somani, Moises Rodriguez Socarrás, et al. Shaping the Undergraduate Curriculum in Europe: Consensus Statement from the European School of Urology. Eur Urol. 2022;82:581–83
Alexander Ng a,b,c,* Aqua Asif b,c Veeru Kasivisvanathan
doi : 10.1016/j.eururo.2022.11.007
Volume 83, Issue 2, February 2023, Pages e58-e59
Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial� [Eur Urol 2022]
Martin Bo ̈gemann a,*, Neal D. Shore b , Matthew R. Smith c , Teuvo L.J. Tammela d , Albertas Ulys e , Egils Vjaters f , Sergey Polyakov g , Mindaugas Jievaltas h , Murilo Luz i , Boris Alekseev j , Thierry Lebret k , Martin Schostak l , Frank Verholen m , Marie-Aude Le Berre n , Shankar Srinivasan o , Jorge Ortiz o , Ateesha F. Mohamed o , Toni Sarapohja p , Karim Fizazi
doi : 10.1016/j.eururo.2022.11.018
Volume 83, Issue 2, February 2023, Page e60
Congress Calendar
doi : 10.1016/j.eururo.2022.12.014
Volume 83, Issue 2, February 2023, Pages e61-e62
The Platinum Hall of Fame
doi : 10.1016/j.eururo.2022.12.013
Volume 83, Issue 2, February 2023, Pages e35-e44
Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy
Laura S. Mertens a,*, Richard P. Meijer b , J. Alfred Witjes
doi : 10.1016/j.eururo.2022.09.017
Volume 83, Issue 2, February 2023, Pages 95-96
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist’s Point of View
Milan Hora a,*, Laurence Albiges b , Jens Bedke c,d , Riccardo Campi e,f,g , Umberto Capitanio h,i , Rachel H. Giles j , Bo ̈rje Ljungberg k , Lorenzo Marconi l , Tobias Klatte m , Alessandro Volpe n , Yasmin Abu-Ghanem o , Saeed Dabestani p , Sergio Ferna �ndez-Pello q , Fabian Hofmann r , Teele Kuusk s , Rana Tahbaz m , Thomas Powles t , Axel Bex u,v,w , Kiril Trpkov
doi : 10.1016/j.eururo.2022.11.001
Volume 83, Issue 2, February 2023, Pages 97-100
Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint
Kerrington Powell a , Michael C. Burns b , Vinay Prasad
doi : 10.1016/j.eururo.2022.08.029
Volume 83, Issue 2, February 2023, Pages 101-102
Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial
Sigrid V. Carlsson a,b,c , Rebecka Arnsrud Godtman c,d , Carl-Gustav Pihl e , Andrew Vickers b , Hans Lilja a,f,g,h , Jonas Hugosson c,d , Marianne Ma ÌŠ nsson c
doi : 10.1016/j.eururo.2022.10.006
Volume 83, Issue 2, February 2023, Pages 103-109
Screening for Prostate Cancer with Prostate-specific Antigen: The Journey Continues
Peter C. Albertsen
doi : 10.1016/j.eururo.2022.10.018
Volume 83, Issue 2, February 2023, Pages 110-111
Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer
Ethan S. Barnett a , Nikolaus Schultz b , Konrad H. Stopsack a , Ernest T. Lam c , Andrea Arfe b , Jerry Lee c , Jimmy L. Zhao a , Joseph D. Schonhoft c , Emily A. Carbone a , Niamh M. Keegan a , Andreas Wibmer d , Yipeng Wang c , David B. Solit a , Wassim Abida a , Richard Wenstrup c , Howard I. Scher
doi : 10.1016/j.eururo.2022.08.010
Volume 83, Issue 2, February 2023, Pages 112-120
BRCA2 alterations predict for a response to poly-ADP-ribose polymerase inhibition in metastatic castration-resistant prostate cancer (mCRPC). However, detection is hindered by insufficient tumor tissue and low sensitivity of cell-free DNA for detecting copy number loss.
Putting Precision Medicine in Prostate Cancer into Practice: Are We There Yet?
Christopher Logothetis *, Patrick Pilie
doi : 10.1016/j.eururo.2022.09.028
Volume 83, Issue 2, February 2023, Pages 121-124
Outpatient Photodynamic Diagnosis–guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis–guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial
Gyrithe Lynghøj Pedersen a,*, Marie Schmidt Erikson a , Karin Mogensen a , Susanne Rosthøj b , Gregers Gautier Hermann
doi : 10.1016/j.eururo.2022.08.012
Volume 83, Issue 2, February 2023, Pages 125-130
Transurethral resection of recurrent low-grade intermediate-risk Ta bladder tumor (BT) in general anesthesia (GA) is burdensome to patients and health care system. Laser technologies enable treatment in office-based settings, reducing morbidity and costs.
Is Office-based Management of Intermediate-risk Low-grade Non–muscle-invasive Bladder Cancer Ready For Prime Time?
Jacob Taylor, Yair Lotan
doi : 10.1016/j.eururo.2022.09.001
Volume 83, Issue 2, February 2023, Pages 131-132
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition
Franziska Erlmeier a,b,c,d,e , Niklas Klu ̈mper f,g,h , Laura Landgraf a,b,e , Pamela L. Strissel a,b,c,e,i , Reiner Strick b,c,e,i , Danijel Sikic b,c,e,j , Helge Taubert b,c,e,j , Sven Wach b,c,e,j , Carol I. Geppert a,b,e , Veronika Bahlinger a,b,c,e , Johannes Breyer c,e,k , Manuel Ritter c,f,h , Christian Bolenz c,l , Florian Roghmann c,m , Philipp Erben c,n , Kristina Schwamborn d,e , Ralph M. Wirtz c,o , Thomas Horn e,p , Bernd Wullich b,c,e,j , Michael Ho ̈lzel g,h , Arndt Hartmann a,b,c,e , Ju ̈rgen E. Gschwend e,p , Wilko Weichert d,e , Markus Eckstein
doi : 10.1016/j.eururo.2022.10.020
Volume 83, Issue 2, February 2023, Pages 133-142
TIME for a Change? Multimarker Assessment of the Tumour Immune Microenvironment and Metastatic Site Biopsy to Improve Immunotherapy Response Prediction in Muscle-invasive Bladder Cancer
Jon Griffin
doi : 10.1016/j.eururo.2022.11.008
Volume 83, Issue 2, February 2023, Pages 143-144
Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium
Ziad Bakouny a,b,c,y, Talal El Zarif b,c,y, Shaan Dudani d , J. Connor Wells e , Chun Loo Gan f , Frede Donskov g,h , Julia Shapiro i , Ian D. Davis j,k , Francis Parnis l , Praful Ravi b,c , John A. Steinharter b , Neeraj Agarwal m , Ajjai Alva n , Lori Wood o , Anil Kapoor p , Jose M. Ruiz Morales q , Christian Kollmannsberger r , Benoit Beuselinck s , Wanling Xie t,y, Daniel Y.C. Heng e,y, Toni K. Choueiri
doi : 10.1016/j.eururo.2022.10.004
Volume 83, Issue 2, February 2023, Pages 145-151
Primary Cytoreductive Nephrectomy: Standing the Test of Time?
Ithaar H. Derweesh a , Rana R. McKay b , Aditya Bagrodia
doi : 10.1016/j.eururo.2022.10.022
Volume 83, Issue 2, February 2023, Pages 152-153
Effect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial
Vladimir Student Jr. a,*, Zbynek Tudos b , Zuzana Studentova a , Ondrej Cesak a , Hana Studentova c , Vaclav Repa d , Dana Purova d , Vladimir Student
doi : 10.1016/j.eururo.2022.07.027
Volume 83, Issue 2, February 2023, Pages 154-162
Symptomatic lymphoceles present the most common complication of robot-assisted radical prostatectomy (RARP) with extended pelvic lymph node dissection (ePLND). No surgical technique has so far shown success in reducing the incidence rate, but several retrospective studies have shown the beneficial effect of the fixation of the peritoneum.
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
Yunze Xu a,y, Wen Kong a,y, Ming Cao a,y, Jieying Wang b , Zaoyu Wang c , Liang Zheng d , Xiaoyu Wu d , Rongrong Cheng d , Wei He c , Bo Yang e , Baijun Dong a , Jiahua Pan a , Yonghui Chen a , Jiwei Huang a , Chen Jiang a , Wei Zhai a , Fangzhou Li a , Ruohua Chen f , Xiang Zhou f , Guangyu Wu g , Xiaochuan Geng g , Jiasheng Chen h , Huimin An i , Yichu Yuan j , Tianyuan Xu k , Dongning Chen l , Dengqiang Lin m , Lieyu Xu n , Kangbo Huang o , Ling Peng p , Yanfei Yu q , Shengcheng Tai r , Honggang Qi s , Kai Luo t , Xiaonan Kang t , Hang Wang u , Yiran Huang a,*, Jin Zhang a,*, Wei Xue
doi : 10.1016/j.eururo.2022.05.029
Volume 83, Issue 2, February 2023, Pages 163-172
FH-deficient renal cell carcinoma (RCC) is a rare and exceptionally aggressive RCC subtype. There is currently limited understanding of the molecular alterations, pathogenesis, survival outcomes, and systemic therapy efficacy for this cancer.
Kidney Transplantation Outcome Predictions (KTOP): A Risk Prediction Tool for Kidney Transplants from Brain-dead Deceased Donors Based on a Large European Cohort
Gregor Miller a,*, Donna P. Ankerst a,b , Michael W. Kattan c , Norbert Hu ̈ser d,e , Serge Vogelaar f , Ineke Tieken f , Uwe Heemann d,g , Volker Assfalg
doi : 10.1016/j.eururo.2021.12.008
Volume 83, Issue 2, February 2023, Pages 173-179
European kidney donation shortages mandate efficient organ allocation by optimizing the prediction of success for individual recipients.
Genitourinary Symptoms Caused by Monkeypox Virus: What Urologists Should Know
Zhikang Yu a,y, Bo Zhu a,y, Qiuqiu Qiu b , Ning Ding a , Haiyang Wu c,d,*, Zefeng Shen
doi : 10.1016/j.eururo.2022.11.005
Volume 83, Issue 2, February 2023, Pages 180-182
Uncertainty Persists Regarding the Role of Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma with Favourable Prognosis
Chiara Ciccarese
doi : 10.1016/j.eururo.2022.10.026
Volume 83, Issue 2, February 2023, Pages e45-e46
Re: Spatially Resolved Clonal Copy Number Alterations in Benign and Malignant Tissue
Karol Axcrona a,b,* Kirsti Aas c Ulrika Axcrona b,d Rolf I. Skotheim
doi : 10.1016/j.eururo.2022.11.013
Volume 83, Issue 2, February 2023, Page 183
Re: Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction
Howard B. Goldman
doi : 10.1016/j.eururo.2022.11.015
Volume 83, Issue 2, February 2023, Page 184
Re: Thulium Fibre Laser versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial
Mariela Corrales Olivier Traxer
doi : 10.1016/j.eururo.2022.11.012
Volume 83, Issue 2, February 2023, Pages 184-185
Re: Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography
Marco Borghesi a,* Matteo Bauckneht b Carlo Terrone
doi : 10.1016/j.eururo.2022.11.016
Volume 83, Issue 2, February 2023, Pages 185-186
Re: Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death
Ana Plata Bello a,* Karim Touijer
doi : 10.1016/j.eururo.2022.12.006
Volume 83, Issue 2, February 2023, Pages 186-187
Re: Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer
Arnauld Villers * Jonathan Olivier
doi : 10.1016/j.eururo.2022.09.023
Volume 83, Issue 2, February 2023, Pages 187-188
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Suman Sahoo * Abhishek Pandey Swarnendu Mandal Manoj Kumar Das Prasant Nayak
doi : 10.1016/j.eururo.2022.10.027
Volume 83, Issue 2, February 2023, Page e47
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Wei Shen Tan a,b,* Connor Mustard c John D. Kelly a,d , on behalf of the HIVEC-II trial team
doi : 10.1016/j.eururo.2022.11.006
Volume 83, Issue 2, February 2023, Pages e48-e49
Re: Albert Martini, Nicolas Mottet, Francesco Montorsi, et al. A Plea for Economically Sustainable Evidence-based Guidelines. Eur Urol. 2022;82:449–51
Minxiong Hu Liefu Ye
doi : 10.1016/j.eururo.2022.10.023
Volume 83, Issue 2, February 2023, Pages e50-e51
Re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique. Eur Urol. 2022;82:551–58
Minxiong Hu Liefu Ye
doi : 10.1016/j.eururo.2022.09.036
Volume 83, Issue 2, February 2023, Pages e52-e53
Re: Khyati Meghani, Lauren Folgosa Cooley, Bonnie Choy, et al. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin. Eur Urol. 2022;82:602–10
Ryan L. Steinberg * Michael A. O’Donnell Vignesh T. Packiam
doi : 10.1016/j.eururo.2022.10.025
Volume 83, Issue 2, February 2023, Pages e54-e55
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Fabio Campodonico a,* Francesca Mattioli b,c Carlo Introini
doi : 10.1016/j.eururo.2022.09.035
Volume 83, Issue 2, February 2023, Pages e56-e57
Re: Juan Gómez Rivas, Bhaskar Somani, Moises Rodriguez Socarrás, et al. Shaping the Undergraduate Curriculum in Europe: Consensus Statement from the European School of Urology. Eur Urol. 2022;82:581–83
Alexander Ng a,b,c,* Aqua Asif b,c Veeru Kasivisvanathan
doi : 10.1016/j.eururo.2022.11.007
Volume 83, Issue 2, February 2023, Pages e58-e59
Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial� [Eur Urol 2022]
Martin Bo ̈gemann a,*, Neal D. Shore b , Matthew R. Smith c , Teuvo L.J. Tammela d , Albertas Ulys e , Egils Vjaters f , Sergey Polyakov g , Mindaugas Jievaltas h , Murilo Luz i , Boris Alekseev j , Thierry Lebret k , Martin Schostak l , Frank Verholen m , Marie-Aude Le Berre n , Shankar Srinivasan o , Jorge Ortiz o , Ateesha F. Mohamed o , Toni Sarapohja p , Karim Fizazi
doi : 10.1016/j.eururo.2022.11.018
Volume 83, Issue 2, February 2023, Page e60
Congress Calendar
doi : 10.1016/j.eururo.2022.12.014
Volume 83, Issue 2, February 2023, Pages e61-e62
